Bone Biologics Corp Common Stock

Day range

$0.37 – $0.41

Open

$0.39

Prev close

$0.39

Volume

25.43K

Market cap

$1.09M

Shares out

2.76M

P/E

—

P/S

—

P/B

0.27

P/FCF

—

ROE

-73.7%

ROA

-65.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsSep 29, 2026

  The Company's stockholders ratified the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Listing deficiency noticeSep 16, 2026

  On September 10, 2026, Bone Biologics Corporation received a letter from Nasdaq indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until March 9, 2027, in which to regain compliance.

• Business updateJul 23, 2026

  On July 23, 2026, Bone Biologics Corporation (the "Company") issued a press release highlighting the corporate, scientific and operational milestones progress across 2026 priorities.

• Shareholder meeting noticeJul 16, 2026

  On July 15, 2026, the Board of Directors determined to postpone the 2026 annual meeting of stockholders, which was previously scheduled to be held on August 11, 2026. The Annual Meeting will be held at the Company's offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803, on September 28, 2026 at 11:30 a.m. Eastern Time and the new record date for the Annual Meeting will be August 6, 2026.

• Warrant or conversionJul 9, 2026

  the Series F Warrants have an exercise price of $1.42 per share of Common Stock, are exercisable beginning on the effective date of stockholder approval of the issuance of the Warrants and shares of Common Stock issuable upon exercise of the Warrants (the "Stockholder Approval Date") and will expire five years from the later of (A) the Stockholder Approval Date and (B) the date the registration statement covering the resale of the shares issuable upon exercise of the Warrants is declared effective by the Securities and Exchange Commission (the "Effective Date"), and (ii) the Series G Warrants have an exercise price of $1.42 per share of Common Stock, are exercisable beginning on the Stockholder Approval Date and will expire eighteen months from the later of (A) the Stockholder Approval Date and (B) the Effective Date.

Days to cover

1.0

Short interest

49.51K

Avg volume

517.97K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
  positiveGlobeNewswire Inc.· Jul 7, 2026
• Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
  positiveGlobeNewswire Inc.· Jan 8, 2026
• Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket
  Benzinga· Mar 4, 2024
• Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
  Benzinga· Feb 22, 2024
• Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
  Benzinga· Dec 29, 2023